Viwat Visuthikraisee

Auransa, Inc. develops biotechnologies and monoclonal antibody medicines. It applies novel data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. The firm offers SMarTR engine, a proprietary automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds for specific patient sub-populations. The company was founded by Pek Yee Lum and Viwat Visuthikraisee and is headquartered in Palo Alto, CA.

Auransa, Inc. develops biotechnologies and monoclonal antibody medicines. It applies novel data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. The firm offers SMarTR engine, a proprietary automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds for specific patient sub-populations. The company was founded by Pek Yee Lum and Viwat Visuthikraisee and is headquartered in Palo Alto, CA.

Auransa, Inc. develops biotechnologies and monoclonal antibody medicines. It applies novel data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. The firm offers SMarTR engine, a proprietary automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds for specific patient sub-populations. The company was founded by Pek Yee Lum and Viwat Visuthikraisee and is headquartered in Palo Alto, CA.

Auransa, Inc. develops biotechnologies and monoclonal antibody medicines. It applies novel data analysis techniques and algorithms to every step of the drug discovery and development pipeline to identify compounds, markers and new targets for specific patient populations. The firm offers SMarTR engine, a proprietary automated and scalable computational platform that characterizes disease heterogeneity and identifies compounds for specific patient sub-populations. The company was founded by Pek Yee Lum and Viwat Visuthikraisee and is headquartered in Palo Alto, CA.